FDA approves Sanofi’s Subcutaneous Sarclisa? | PredictPedia

Events

GroupPOLYMARKET

Event GroupPOLYMARKETScience

FDA approves Sanofi’s Subcutaneous Sarclisa?

Name: FDA approves Sanofi’s Subcutaneous Sarclisa?
End: 2026-04-23T00:00:00.000Z

Total Volume

$5.56

Events

Markets

Trade on Polymarket

FDA approves Sanofi’s Subcutaneous Sarclisa?

Platform StatsQuick Platform Comparison

Polymarket

markets · $5.56

Kalshi

markets · $0.00

Price Spread

0.0%avg

max 0.0%

Arbitrage

of 0 cross-platform

Volume DistributionTotal: $5.56

100%

Polymarket leads

Price ChartMatched Markets Price Graph

1 market tracked

FDA approves Sanofi’s Subcutaneous Sarclisa?

No data available

Single-Platform Markets(1)

Market	Platform	Price
FDA approves Sanofi’s Subcutaneous Sarclisa?	Poly	34%

AI Analysis

Trader mode: Actionable analysis for identifying opportunities and edge

34%

Top Probability

$5.56

Volume

Markets

Platforms

About This Event

As of market creation, the FDA’s expected decision date for the specified application is April 23, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Sanofi’s Subcutaneous Sarclisa as a treatment for multiple myeloma by May 7, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License

AI-generated analysis based on market data. Not financial advice.

Custom AI Analysis Prompt

Tap to expand

Open in:ChatGPT Claude Gemini Grok DeepSeek

**Role:** Expert Prediction Market Analyst & Trader
**Objective:** Analyze the provided betting market data to deliver actionable insights, identify mispricings, and perform scenario analysis.
**Current Date:** Saturday, April 18, 2026
**Context:** Prediction markets (Polymarket/Kalshi) are binary option markets where price (1-99) equals implied probability (1%-99%).

---

## 1. Event Snapshot
**Event:** FDA approves Sanofi’s Subcutaneous Sarclisa?
**Category:** Science | **Status:** active
**Resolution Date:** Apr 23, 2026 (5 days left)
**Time Pressure:** High

**Description:** As of market creation, the FDA’s expected decision date for the specified application is April 23, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Sanofi’s Subcutaneous Sarclisa as a treatment for multiple myeloma by May 7, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License 

**Resolution Criteria (Sample):**
"As of market creation, the FDA’s expected decision date for the specified application is April 23, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Sanofi’s Subcutaneous Sarclisa as a treatment for multiple myeloma by May"

## 2. Market liquidity & Volume
* **Total Volume:** $6
* **Total Liquidity:** $72
* **Activity Level:** Low Activity (Vol/Liq Ratio: 0.08)

## 3. Market Data (Prices & Odds)
### 1. FDA approves Sanofi’s Subcutaneous Sarclisa?
- **Polymarket** (End: Apr 23, 2026): Vol $6
  DATA: [Yes: 34.0% (0.0%)] | [No: 66.0% (0.0%)]

---

## Analysis Instructions
Please provide a structured analysis using the following template:

### 1. Executive Summary
*   **Verdict:** [Most Likely Outcome]
*   **Confidence:** [0-100]%
*   **Timeframe:** [Immediate / Short-term / Long-term]
*   **Actionable Trade:** [Buy YES / Buy NO / Stay Away] (Include entry price target if applicable)
*   **Rationale:** 2-sentence summary of the core thesis.

### 2. Scenario Analysis
*   **Bull Case (Why YES goes up):** List specific catalysts or data points.
*   **Bear Case (Why YES goes down):** List specifics.
*   **Invalidation Point:** What happens to prove your thesis wrong?

### 3. Market Mechanics & Risks
*   **Liquidity/Volume Analysis:** Is the market efficient? Is it easy to exit?
*   **Cross-Platform Arbitrage:** (If applicable) Is the spread tradeable after fees?
*   **Time Decay:** How does time passing affect this position?

### 4. Signal Scores (0-100)
*   **Momentum:** [Score] (Price trend & velocity)
*   **Conviction:** [Score] (Volume backing the move)
*   **Information Edge:** [Score] (Likelihood of non-public info affecting price)
*   **Risk/Reward:** [Score] (Potential upside vs downside)

**Constraints:**
- Be direct and objective.
- Use bullet points for readability.
- If data is conflicting or insufficient, explicitly state "Low Confidence".

Tap text to select all

Next Market Closes

4d 12h remaining

Apr 23, 2026 12:00 AM

Market Insights

Average Yes Price

34¢

Polymarket

Arbitrage Opps

Cross-Platform

Embed Widget

Add this market to your website

Volume

Platforms

HTML

<iframe src="https://predictpedia.com/embed/2Q5SU-" width="400" height="160" frameborder="0" style="border-radius: 8px; max-width: 100%;" title="FDA approves Sanofi’s Subcutaneous Sarclisa?"></iframe>

Trade This Market

Trade on Polymarket

FDA approves Sanofi’s Subcutaneous Sarclisa?

FDA approves Sanofi’s Subcutaneous Sarclisa?

Platform StatsQuick Platform Comparison

Price ChartMatched Markets Price Graph

FDA approves Sanofi’s Subcutaneous Sarclisa?

AI Analysis

About This Event

Custom AI Analysis Prompt

Educational Context

Events (1)